Currently, Bio-Rad Laboratories Inc [BIO] is trading at $220.51, down -3.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BIO shares have lost -8.12% over the last week, with a monthly amount drifted -11.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Rad Laboratories Inc [NYSE: BIO] stock has seen the most recent analyst activity on October 01, 2024, when Citigroup upgraded its rating to a Buy and also boosted its price target to $400 from $350. Previously, Wells Fargo started tracking the stock with Equal Weight rating on August 28, 2024, and set its price target to $340. Citigroup downgraded its rating to a Neutral and decreased its price target to $365 on April 03, 2024. UBS initiated its recommendation with a Buy and recommended $395 as its price target on December 07, 2023. Wells Fargo started tracking with a Overweight rating for this stock on June 16, 2023, and assigned it a price target of $550. In a note dated December 07, 2022, RBC Capital Mkts initiated an Outperform rating and provided a target price of $565 on this stock.
This stock has fluctuated between a low of $215.38 and a high of $387.99 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $482.5 within the next 12 months. Bio-Rad Laboratories Inc [NYSE: BIO] shares were valued at $220.51 at the most recent close of the market. An investor can expect a potential return of 118.81% based on the average BIO price forecast.
Analyzing the BIO fundamentals
Trailing Twelve Months sales for Bio-Rad Laboratories Inc [NYSE:BIO] were 2.57B which represents -2.01% decline. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at -0.91%, and Net Profit Margin reading is -0.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 215.00 points at the first support level, and at 209.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 231.10, and for the 2nd resistance point, it is at 241.70.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bio-Rad Laboratories Inc [NYSE:BIO] is 6.48. In addition, the Quick Ratio stands at 4.85 and the Cash Ratio stands at 1.04. Considering the valuation of this stock, the price to sales ratio is 2.41, the price to book ratio is 0.94.
Transactions by insiders
Recent insider trading involved Crowley Michael, EVP, GBL Commercial Operations, that happened on Mar 14 ’25 when 3000.0 shares were sold. Officer, Crowley Michael completed a deal on Mar 13 ’25 to buy 3000.0 shares. Meanwhile, Director Alles Institute for Medical Re bought 410.0 shares on Mar 11 ’25.
